AACR 2023

AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor

This poster was presented at the 2023 AACR Annual Meeting.

To read the full study report download the poster.